Glutamic Acid Decarboxylase Antibody
| Abbrev Code: | GAD | ||
| Order Code: | LAB3488 | Order Name: | Glutamic Acid Decarboxylase Antibody |
| Synonyms: | GAD65 | ||
| Methodology: | Enzyme-linked immunosorbent assay | ||
| CPT Codes: | 86341 x1 | ||
| Turnaround Time: | Specimens are sent to reference laboratory Mon-Sat; results are reported in 1-3 days. | ||
Collection Instructions
| Specimen: | Blood |
| Optimal Volume: | 2 mL |
| Minimum\Peds Volume: | 1.2 mL |
| Container: | Red or gold (gel) Alternate Containers: Red (no gel) |
| Causes for Rejection: | Plasma, grossly hemolyzed specimens |
Processing and Shipping
| Specimen Processing: | Centrifuge and aliquot 1 mL, 0.5 mL minimum. Store in freezer. |
| Shipping Instructions: | Ship on dry ice. |
| Stability: | 24 hours at room temperature; 1 week refrigerated; 3 months frozen. |
| Test Performed at or Referral Lab | Lab Sendouts (ARUP) |
| Referral Lab number: | 2001771 |
Interpretive
| Reference Range: | 0.0-5.0 IU/mL
A value greater than 5.0 Kronos IU/mL is considered positive for Glutamic Acid Decarboxylase Antibody. |
| Use: | GAD antibodies are present in the majority of individuals with new-onset diabetes and in individuals in the prediabetic phase of the disease. GAD antibodies appear early in the disease process prior to clinical symptoms and can be used to produce who will develop IDDM. Because GAD antibody is present in association with islet cell destruction, it can also be utilized to differentiate IDDM from non-insulin dependent diabetes (NIDDM). The development of GAD antibody in NIDDM patients can be useful to determine which patients may later require insulin therapy. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 3849"